Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

HSBC raised the firm’s price target on Eli Lilly (LLY) to $1,070 from $850 and keeps a Hold rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well ...

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

In a crowded GLP-1 race dominated by giants, retail traders are siding with Novo Nordisk for the long haul, according to a 1,100-vote Stocktwits poll that pushes Hims & Hers, Viking Therapeutics and ...

S&P 500 heads for weakest November since 2021 as AI fears hit stocks; Albemarle and Eli Lilly surge while Super Micro and ...

The ranking of the most profitable companies in the world in 2025 highlights a strong concentration of earnings in the fields ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Eli Lilly to invest $6 billion in new synthetic medicine facility in Huntsville, AL to boost domestic production and create ...

A major pharmaceutical company is making an announcement on Tuesday regarding growth of biopharma innovation in the Rocket ...

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster medicine supply ...